Pink SheetThe US Food and Drug Administration’s recent safety labeling changes quantifying the myocarditis risk with COVID-19 mRNA vaccines are unlikely to quell the concerns of Centers for Disease Control and
ScripThe market for BCMA-directed therapies to treat multiple myeloma just got a little more crowded with the US Food and Drug Administration giving the green light to Regeneron Pharmaceuticals’ Lynozyfic
ScripModerna appears to have a pathway to approval for its investigational influenza/COVID-19 combination vaccine mRNA-1083 now that it reported positive Phase III efficacy data on June 30 for mRNA-1010, a
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear